Merck & Company Inc (MRK)

NYSE
Currency in USD
80.96
-0.75(-0.92%)
Closed·
After Hours
80.94-0.02(-0.02%)
·
MRK Scorecard
Full Analysis
Has raised its dividend for 14 consecutive years
MRK is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
79.7181.35
52 wk Range
73.31134.63
Key Statistics
Edit
Prev. Close
81.71
Open
80.88
Day's Range
79.71-81.35
52 wk Range
73.31-134.63
Volume
12.57M
Average Volume (3m)
16.09M
1-Year Change
-37.47%
Book Value / Share
19.13
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MRK Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
101.79
Upside
+25.73%
Members' Sentiments
Bearish
Bullish
ProTips
10 analysts have revised their earnings downwards for the upcoming period

Merck & Company Inc News & Analysis

Show more

Merck & Company Inc Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Employees
74000

Merck & Company Inc SWOT Analysis


Keytruda's Dominance
Explore Merck's reliance on Keytruda for growth and the looming challenges of its patent expiration, including strategies to maintain market share
China Market Turmoil
Delve into Merck's unexpected pause in Gardasil sales in China, highlighting the volatility of this key market and its impact on revenue forecasts
Pipeline Potential
Learn about Merck's promising drug candidates, including enlicitide and clesrovimab, that could drive future growth and offset potential losses
Strategic Outlook
Analysts project a price target range of $84 to $145, reflecting varied views on Merck's ability to navigate upcoming challenges and capitalize on opportunities
Read full SWOT analysis

Merck & Company Inc Earnings Call Summary for Q1/2025

  • Q1 2025 EPS of $2.22 beat $2.14 forecast; revenue of $15.5B exceeded projections despite 2% YoY decrease
  • Keytruda sales grew 6% to $7.2B; Gardasil sales in China reduced overall revenues by $1.1B
  • Full-year revenue guidance maintained at $64.1B-$65.6B; EPS expected between $8.82-$8.97
  • Stock fell 0.88% pre-market despite earnings beat; analysts revise earnings upward for upcoming period
  • CEO emphasizes focus on innovation; company addresses strategies for Keytruda patent expiration and market challenges
Last Updated: 25/04/2025, 12:34 am
Read Full Transcript

Compare MRK to Peers and Sector

Metrics to compare
MRK
Peers
Sector
Relationship
P/E Ratio
11.7x17.7x−0.5x
PEG Ratio
0.020.140.00
Price/Book
4.2x1.5x2.6x
Price / LTM Sales
3.2x4.2x3.1x
Upside (Analyst Target)
21.8%80.0%48.6%
Fair Value Upside
Unlock17.8%8.9%Unlock

Analyst Ratings

15 Buy
10 Hold
0 Sell
Ratings:
25 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 101.79
(+25.73% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 6.89%
Dividend Yield
3.97%
Industry Median 1.73%
Annualised payout
3.24
Paid quarterly
5-Years Growth
+6.66%
Growth Streak

Earnings

Latest Release
Apr 24, 2025
EPS / Forecast
2.22 / 2.14
Revenue / Forecast
15.53B / 15.33B
EPS Revisions
Last 90 days

MRK Income Statement

People Also Watch

307.66
UNH
-1.87%
190.86
ABBV
-0.12%
101.95
FTNT
+1.11%
176.55
AMAT
+3.49%
48.66
BMY
-2.19%

FAQ

What Is the Merck&Co (MRK) Stock Price Today?

The Merck&Co stock price today is 80.96

What Stock Exchange Does Merck&Co Trade On?

Merck&Co is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Merck&Co?

The stock symbol for Merck&Co is "MRK."

Does Merck&Co Pay Dividends? What’s The Current Dividend Yield?

The Merck&Co dividend yield is 4%.

What Is the Merck&Co Market Cap?

As of today, Merck&Co market cap is 203.29B.

What Is Merck&Co's Earnings Per Share (TTM)?

The Merck&Co EPS (TTM) is 6.89.

When Is the Next Merck&Co Earnings Date?

Merck&Co will release its next earnings report on 28 July 2025.

From a Technical Analysis Perspective, Is MRK a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Merck&Co Stock Split?

Merck&Co has split 5 times.

How Many Employees Does Merck&Co Have?

Merck&Co has 74000 employees.

What is the current trading status of Merck&Co (MRK)?

As of 16 June 2025, Merck&Co (MRK) is trading at a price of 80.96, with a previous close of 81.71. The stock has fluctuated within a day range of 79.71 to 81.35, while its 52-week range spans from 73.31 to 134.63.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.